Vicor Q3 Shatters Expectations; Supply Expansion Now Dated

What happened

Vicor reported record Q3 revenue of $197.1 million, up 78.5% year over year, with royalties surging 207% and gross margin reaching 68.3%, far exceeding the prior report's base case. The company remains supply-constrained, with Fab 1 nearly full and two new fab sites targeting about 5x capacity by Q2 2027, directly addressing the capacity risk highlighted in the master report. The exceptional royalty jump—estimated at roughly $67 million versus $30 million in Q2—strengthens the licensing monetization thesis but also raises questions about one-time factors versus recurring revenue. Following a 38% drawdown since the analyst's last article, the stock may now trade near the previously identified attractive entry zone of $175. Overall, the Q3 results shift the balance of evidence toward the bull scenario, though royalty durability and execution on capacity expansion remain key watch items.

Implication

The Q3 beat materially strengthens the investment case, particularly on royalty momentum and capacity expansion, but the sustainability of the royalty surge is unproven. If the stock trades below the prior $175 attractive entry level, current prices may offer an improved margin of safety relative to the master report's analysis. However, one quarter does not confirm recurring royalty levels, and investors should demand evidence of royalty durability in subsequent quarters. Capacity expansion timing has become more specific, but execution risks remain, especially given the company's history of vague fab timelines. Until further confirmation, the risk-reward balance has shifted more positive, yet strict discipline on entry price and ongoing monitoring of royalty and capacity milestones are still advisable.

Thesis delta

The prior WAIT rating was contingent on proof of royalty durability above $25 million per quarter and a dated capacity roadmap. Q3 results show royalties surged to an estimated $67 million, far exceeding the threshold, and management has targeted 5x capacity by Q2 2027. This shifts the thesis toward the bull case, though one quarter does not confirm recurring royalty levels, and valuation must be re-checked against updated earnings to confirm an adequate margin of safety.